Avadel Pharmaceuticals plc - Ordinary Share (AVDL)

Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whether the new proposal could be superior.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.

A new bidding war could kick off in biotech with Avadel Pharmaceuticals at the center.

Avadel’s board of directors is of the opinion that the fresh proposal would reasonably be expected to be considered superior to the company’s existing agreement with Alkermes.

Avadel Pharmaceuticals (AVDL) meets the Mark Minervini Trend Template with a strong technical uptrend and accelerating earnings and sales growth momentum.

Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across various sectors.

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.

DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for a staggering $2.1 billion. The news sent Avadel's stock price soaring in premarket trading, reflecting a significant premium offered to its investors.

The companies are both working in the sleep space, focusing on excessive daytime sleepiness.

Alkermes will buy Avadel for up to $20 per share.

Avadel Pharmaceuticals (AVDL) beats Q2 2025 estimates with $68.1M revenue and $0.10 EPS, driven by strong LUMRYZ™ adoption. Stock surges 6.3% pre-market.

ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options

ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according to a WSJ report.